Evening Brief: One-Shot Gene Therapy CTX310 Shows Promise for Refractory Hyperlipidemia; New Study Finds No Clear Link Between Tylenol and Autism

(Source:BioValley）

Source: Bioon

1. Stubborn Hyperlipidemia, One Shot Solution: The World's First Gene-Editing Therapy, Long-Term Medication Dilemma May Meet Its End

The New England Journal of Medicine reported that CTX310, the world’s first therapy utilizing CRISPR-Cas9 gene-editing technology to target ANGPTL3, demonstrated favorable safety and efficacy in a Phase I clinical trial for refractory hyperlipidemia. ANGPTL3 is a protein synthesized by the liver that inhibits the activity of lipoprotein lipase and endothelial lipase, affecting the metabolism of triglycerides and low-density lipoprotein cholesterol (LDL-C). Individuals with natural mutations (loss-of-function) in the ANGPTL3 gene exhibit significantly lower levels of LDL-C and triglycerides compared to the general population, along with a reduced risk of cardiovascular disease. Administered through a single intravenous injection, CTX310 specifically targets the ANGPTL3 gene in hepatocytes, inducing loss-of-function mutations to achieve long-term effective lipid management. Preclinical studies showed that CTX310 has high specificity, with no significant off-target editing observed, offering patients a potentially "long-lasting" solution for lipid control. This breakthrough could end the long-standing challenge of chronic medication use, bringing new hope to patients with refractory hyperlipidemia.

2. New Study Says Tylenol and Autism Have No Clear Link

Evidence Review Published in The BMJ Shows No Clear Link Between Prenatal Acetaminophen (Tylenol) Use and Autism or ADHD in Children. Researchers Evaluated Nine Systematic Reviews, Covering 40 Observational Studies, and Found Most Studies Had a High Risk of Bias and Did Not Adequately Adjust for Family Genetic and Environmental Factors. After Adjustment, Two Studies Showed the Association Between Acetaminophen Exposure and the Risk of Autism and ADHD in Children Disappeared or Weakened. Therefore, Regulators, Clinicians, and Pregnant Women Should Be Aware of the Quality Limitations of Current Assessments and Be Informed That Acetaminophen Can Be Taken as Needed to Relieve Pain and Fever Symptoms When Necessary.

3. Mait Medical Completes Tens of Millions of Yuan in Angel Financing, Leading Innovation in Bioenergy Medical New Materials and Biodegradable 3D-Printed Implants

Recently, Xi'an Might Medical New Materials Technology Co., Ltd. (hereinafter referred to as "Might Medical") has completed a financing of nearly 50 million yuan, led by Shaanxi Jincheng Fund, with co-investment from Jingwei Heying, Chipunity Technology Group, Pulite Investment, Xincheng Investment, and Daiguan Chemicals. Meanwhile, Might Medical announced the completion of the merger and reorganization of Tongguang Bio. The funds raised will be used for the establishment of production lines for new bioactive raw materials, the certification of 3D-printed artificial bones, and the research and development of new medical aesthetics products.

Mighty Medical Materials, established by merging the research foundation of Xi'an Jiaotong University's scientific research team in the field of high-activity medical key raw materials with Tongguang Bio's industrial experience in biodegradable medical devices, focuses on the research and supply of medical-grade bioactive/bioenergetic medical materials, as well as the development of innovative orthopedic/dental medical devices and medical aesthetic devices.

4. Resight Therapeutics Completes Angel Financing, Focusing on iPSC Ophthalmic Cell Therapy

Resight Therapeutics Completes Tens of Millions of Yuan in Angel Round Financing

5. Yuanpin Bio Stem Cell Treatment for Acute Respiratory Distress Syndrome Clinical Trial Initiated

Source Cell Biotechnology Group (China MedicineResight Therapeutics' independently developed "Human Amniotic Mesenchymal Stem Cell Injection" has officially launched its Phase I clinical trial for the treatment of moderate to severe Acute Respiratory Distress Syndrome (ARDS), with clinical implementation jointly undertaken by Xiangya Hospital and the Third Xiangya Hospital of Central South University. This stem cell drug received Investigational New Drug (IND) approval from the National Medical Products Administration in December 2024, with an indication for clinically urgent, critically ill moderate to severe ARDS. Prior research has shown that human amniotic mesenchymal stem cells, through the secretion of anti-inflammatory and growth factors, inhibit excessive inflammatory responses in the lungs, promote tissue repair and angiogenesis, while their exosomes protect alveolar macrophages and epithelial cells, reduce cellular damage, and achieve therapeutic effects of alleviating lung injury and promoting pulmonary function recovery.